Avacta Group PLC Director/PDMR Shareholding (5787H)
March 13 2018 - 7:02AM
UK Regulatory
TIDMAVCT
RNS Number : 5787H
Avacta Group PLC
13 March 2018
13 March 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director/PDMR Shareholding
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that its Chief
Executive Officer, Dr Alastair Smith has today purchased 35,800
ordinary shares of 10p each ("Ordinary Shares") at a price of
41.92p per Ordinary Share.
Following this transaction, Dr Smith's total beneficial interest
in the Group is 606,309 Ordinary Shares, representing approximately
0.9% of Avacta's issued share capital. In addition, Alastair Smith
has a joint interest in 1,640,000 shares in the share capital of
the Company; such shares are jointly held by certain Directors
individually and Avacta Group Trustee Limited in its capacity as
trustee of The Avacta Employees' Share Trust.
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane / Nikita
Jain - Corporate Broking
Tel: +44 (0)
WG Partners 203 705 9318
David Wilson Tel: +44 (0)
Nigel Barnes 203 705 9217
Claes Spang www.wgpartners.co.uk
Yellow Jersey PR (Financial Media Tel: +44 (0)7764
and IR) 947137
Sarah Hollins avacta@yellowjerseypr.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities / person closely associated
------- ----------------------------------------------------------------------------
a) Name Alastair Smith
------- ----------------------------------- ---------------------------------------
2. Reason for the Notification
------- ----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------- ----------------------------------- ---------------------------------------
b) Initial notification/Amendment Initial notification
------- ----------------------------------- ---------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
------- ----------------------------------------------------------------------------
a) Name Avacta Group Plc
------- ----------------------------------- ---------------------------------------
b) LEI 2138009U3EG31OPMGH36
------- ----------------------------------- ---------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
------- ----------------------------------------------------------------------------
a) Description of Ordinary shares
the Financial of 10p
instrument, type
of instrument
-------
Identification GB00BYYW9G87
code
------- ----------------------------------- ---------------------------------------
b) Nature of the Purchase of ordinary shares
transaction
------- ----------------------------------- ---------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ----------------- --------------
41.92 pence 35,800
----------------- --------------
------- ----------------------------------- ---------------------------------------
d) Aggregated information:
* Aggregated volume See above
* Price
------- ----------------------------------- ---------------------------------------
e) Date of the transaction 13 March 2018
------- ----------------------------------- ---------------------------------------
f) Place of the London Stock Exchange, AIM
transaction Market (XLON)
------- ----------------------------------- ---------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFKNDKBBKDKND
(END) Dow Jones Newswires
March 13, 2018 08:02 ET (12:02 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024
